PortalPublikationenSerial 18F-FDG PET for Monitoring Treatment Response After A...

Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis

Standard

Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis. / Derlin, Thorsten; Alchalby, Haefaa; Bannas, Peter; Laqmani, Azien; Ayuketang, Francis Ayuk; Triviai, Ioanna; Kreipe, Hans-Heinrich; Bengel, Frank M; Kröger, Nicolaus-Martin.

in: J NUCL MED, Jahrgang 57, Nr. 10, 10.2016, S. 1556-1559.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Derlin, T, Alchalby, H, Bannas, P, Laqmani, A, Ayuketang, FA, Triviai, I, Kreipe, H-H, Bengel, FM & Kröger, N-M 2016, 'Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis', J NUCL MED, Jg. 57, Nr. 10, S. 1556-1559. https://doi.org/10.2967/jnumed.115.166348

APA

Derlin, T., Alchalby, H., Bannas, P., Laqmani, A., Ayuketang, F. A., Triviai, I., Kreipe, H-H., Bengel, F. M., & Kröger, N-M. (2016). Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis. J NUCL MED, 57(10), 1556-1559. https://doi.org/10.2967/jnumed.115.166348

Vancouver

Derlin T, Alchalby H, Bannas P, Laqmani A, Ayuketang FA, Triviai I et al. Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis. J NUCL MED. 2016 Okt;57(10):1556-1559. https://doi.org/10.2967/jnumed.115.166348

Bibtex

@article{c11b8bc5aa854345a3474da20e37b305,
title = "Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis",
abstract = "Our objective was to assess the feasibility of (18)F-FDG PET/CT for noninvasive monitoring of treatment response after allogeneic stem cell transplantation (SCT) for myelofibrosis.METHODS: Twelve patients with myelofibrosis underwent (18)F-FDG PET/CT before and after SCT. Bone marrow uptake, spleen uptake, and spleen size were assessed before and after SCT and compared with hematologic response criteria and bone marrow biopsies.RESULTS: All patients who did not achieve complete remission remained PET-positive (P = 0.02). Extent of disease, bone marrow metabolism, spleen metabolism, and spleen volume decreased significantly in patients with complete remission (P = 0.03). PET/CT after SCT had a sensitivity of 1.0 (95% confidence interval [CI], 0.54-1.0), a specificity of 0.83 (95% CI, 0.36-1.0), a negative predictive value of 1.0 (95% CI, 0.48-1.0), and a positive predictive value of 0.86 (95% CI, 0.42-1.0) for diagnosis of residual disease.CONCLUSION: (18)F-FDG PET/CT is feasible for noninvasive monitoring of treatment response after allogeneic SCT for myelofibrosis.",
author = "Thorsten Derlin and Haefaa Alchalby and Peter Bannas and Azien Laqmani and Ayuketang, {Francis Ayuk} and Ioanna Triviai and Hans-Heinrich Kreipe and Bengel, {Frank M} and Nicolaus-Martin Kr{\"o}ger",
note = "{\textcopyright} 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.",
year = "2016",
month = oct,
doi = "10.2967/jnumed.115.166348",
language = "English",
volume = "57",
pages = "1556--1559",
journal = "J NUCL MED",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "10",

}

RIS

TY - JOUR

T1 - Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis

AU - Derlin, Thorsten

AU - Alchalby, Haefaa

AU - Bannas, Peter

AU - Laqmani, Azien

AU - Ayuketang, Francis Ayuk

AU - Triviai, Ioanna

AU - Kreipe, Hans-Heinrich

AU - Bengel, Frank M

AU - Kröger, Nicolaus-Martin

N1 - © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

PY - 2016/10

Y1 - 2016/10

N2 - Our objective was to assess the feasibility of (18)F-FDG PET/CT for noninvasive monitoring of treatment response after allogeneic stem cell transplantation (SCT) for myelofibrosis.METHODS: Twelve patients with myelofibrosis underwent (18)F-FDG PET/CT before and after SCT. Bone marrow uptake, spleen uptake, and spleen size were assessed before and after SCT and compared with hematologic response criteria and bone marrow biopsies.RESULTS: All patients who did not achieve complete remission remained PET-positive (P = 0.02). Extent of disease, bone marrow metabolism, spleen metabolism, and spleen volume decreased significantly in patients with complete remission (P = 0.03). PET/CT after SCT had a sensitivity of 1.0 (95% confidence interval [CI], 0.54-1.0), a specificity of 0.83 (95% CI, 0.36-1.0), a negative predictive value of 1.0 (95% CI, 0.48-1.0), and a positive predictive value of 0.86 (95% CI, 0.42-1.0) for diagnosis of residual disease.CONCLUSION: (18)F-FDG PET/CT is feasible for noninvasive monitoring of treatment response after allogeneic SCT for myelofibrosis.

AB - Our objective was to assess the feasibility of (18)F-FDG PET/CT for noninvasive monitoring of treatment response after allogeneic stem cell transplantation (SCT) for myelofibrosis.METHODS: Twelve patients with myelofibrosis underwent (18)F-FDG PET/CT before and after SCT. Bone marrow uptake, spleen uptake, and spleen size were assessed before and after SCT and compared with hematologic response criteria and bone marrow biopsies.RESULTS: All patients who did not achieve complete remission remained PET-positive (P = 0.02). Extent of disease, bone marrow metabolism, spleen metabolism, and spleen volume decreased significantly in patients with complete remission (P = 0.03). PET/CT after SCT had a sensitivity of 1.0 (95% confidence interval [CI], 0.54-1.0), a specificity of 0.83 (95% CI, 0.36-1.0), a negative predictive value of 1.0 (95% CI, 0.48-1.0), and a positive predictive value of 0.86 (95% CI, 0.42-1.0) for diagnosis of residual disease.CONCLUSION: (18)F-FDG PET/CT is feasible for noninvasive monitoring of treatment response after allogeneic SCT for myelofibrosis.

U2 - 10.2967/jnumed.115.166348

DO - 10.2967/jnumed.115.166348

M3 - SCORING: Journal article

C2 - 27230931

VL - 57

SP - 1556

EP - 1559

JO - J NUCL MED

JF - J NUCL MED

SN - 0161-5505

IS - 10

ER -